230000002633 protecting Effects 0.000 claims description 2.230000003190 augmentative Effects 0.000 claims description 3.125000000539 amino acid group Chemical group 0.000 claims description 5.230000035897 transcription Effects 0.000 claims description 7.125000003729 nucleotide group Chemical group 0.000 claims description 7.239000002773 nucleotide Substances 0.000 claims description 7.230000001939 inductive effect Effects 0.000 claims description 10.208000001756 Virus Disease Diseases 0.000 claims description 10.239000012472 biological sample Substances 0.000 claims description 12.229920001850 Nucleic acid sequence Polymers 0.000 claims description 19.108010076039 Polyproteins Proteins 0.000 claims description 29.102000011587 Polyproteins Human genes 0.000 claims description 29.108020004707 nucleic acids Proteins 0.000 claims description 30.150000001413 amino acids Chemical class 0.000 claims description 35.230000028993 immune response Effects 0.000 claims description 36.125000003275 alpha amino acid group Chemical group 0.000 claims description 38.230000014509 gene expression Effects 0.000 claims description 41.150000007523 nucleic acids Chemical class 0.000 claims description 43.239000002157 polynucleotide Substances 0.000 claims description 52.229920000023 polynucleotide Polymers 0.000 claims description 52.108090000623 proteins and genes Proteins 0.000 claims description 111.102000004169 proteins and genes Human genes 0.000 claims description 111.230000001684 chronic Effects 0.000 claims abstract description 34.239000000203 mixture Substances 0.000 claims abstract description 72.241000711549 Hepacivirus C Species 0.000 claims abstract description 454.229960005486 vaccines Drugs 0.000 title claims abstract description 122.229920000453 Consensus sequence Polymers 0.000 title claims abstract description 284.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority claimed from US64855005P external-priority Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University Priority to US11/815,203 priority Critical patent/US8168771B2/en Priority to EP06734155A priority patent/EP1846439A2/en Publication of WO2006086188A2 publication Critical patent/WO2006086188A2/en Publication of WO2006086188A3 publication Critical patent/WO2006086188A3/en Links Thomas Original Assignee The Johns Hopkins University Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2006086188A2 - Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants WO2006086188A2 - Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
0 kommentar(er)
